Hexamethylcyclotrisiloxane

We are Hexamethylcyclotrisiloxane CAS:541-05-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Hexamethylcyclotrisiloxane
CAS.NO:541-05-9
Synonyms:hexamethyl-cyclotrisiloxan; hexamethylcyclortrisiloxane; 
hexamethyltrisiloxane; Cyclotrisiloxane, hexamethyl-;
Molecular Formula:C6H18O3Si3
Molecular Weight:222.46200
 
Physical and Chemical Properties:
Density:1.02;
Melting point:50-64oC;
Boiling point:134oC;
Flash point:35oC;
Index of Refraction:1.417;
 
Specification:
Appearance:White crystalline solid
Purity(GC):≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:It may be used as synthetic equivalents for the reactive intermediate dimethylsilanone.
It may be used as an effective trapping reagent for a variety of short-lived intermediates, including silanones and silyenes.
It may be used to synthesize many kinds of organic silicone products, which have better stability, better insulation properties and better water resistance.
It may be used to synthesize silicon rubber, which may has better elasticity, better abrasive resistance, and better corrosive resistance.
It may be used to synthesize silicone oil, which may has lower freezing point and less surface tension, it is slightly affected by temperature.

Hexamethylcyclotrisiloxane


Related News: The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.Kojic Acid Dipalmitate CAS:79725-98-7 Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.Tetrahidrotiopiran-4-ona CAS:1072-72-6 INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.34036-80-1 This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved.At the same time, through years of imitation and advanced technology learning, more and more domestic companies have participated in the field of highly original and characteristic APIs.

Related Products
Product Name
Grubbs Catalyst Cas:172222-30-9 View Details
DIMETHYL DISULFIDE Cas:624-92-0 View Details
Gestonoronacetat Cas:31981-44-9 View Details
fendizoic acid Cas:84627-04-3 manufacturer Ertugliflozin L-pyroglutamic Acid Cas:1210344-83-4 manufacturer 1-Bromobutane Cas:109-65-9 manufacturer 3-bromo-n N-diphenylaniline 97 Cas:78600-33-6 manufacturer methyllithium Cas:917-54-4 manufacturer